Kim Yongju, Rigachem Chairman: "A Chinese Tsunami Is Coming, We Need a Game-Changing Lead"
Rigakem R&D Day Held in Yeouido on July 8
Secures 1 Trillion Won Investment Including National Growth Fund
"We Will Lead Late-Stage Clinical Trials to Enhance Corporate Value"
Yongju Kim, Chairman of Rigakem Bioscience, emphasized the urgent need to secure “disruptive gap technologies” in response to the growing threat posed by China’s rapid advances in the bio industry.
At a press conference for ‘Global R&D Day 2026’ held on July 8 at the Conrad Hotel in Yeouido, Seoul, Chairman Kim stated, “Patents are generally protected for about 20 years, but once you have about five to six years left before expiration, ‘counterfeit’ products begin to appear. The only way to stay ahead of China, which relies on overwhelming volume strategies, is to keep running further, making it impossible for them to catch up. We must achieve a breakthrough that fundamentally transforms the landscape, shattering the existing paradigm of antibody-drug conjugates (ADC) and creating a truly disruptive gap.”
To this end, the company began researching new delivery vehicles five years ago and plans to secure a distinct technological lead over competitors by combining proprietary in-house research with proactive open innovation initiatives.
The Era of Rigakem Bioscience 2.0... Accelerating Clinical Trials to Secure 20 ADC Pipeline Candidates
Sejin Park, CEO of Rigakem Bioscience, announced the ‘LCB 2.0’ vision as a mid- to long-term business strategy to respond to these market changes. CEO Park explained the background for this strategy, saying, “In 2023, as competitors were acquired by big pharma and a wave from China surged, we felt a sense of urgency that our existing competitive advantages alone would not guarantee the next five or ten years.” The company defined the period from filing its first ADC patents in 2011 and accumulating related expertise until 2020 as the ‘1.0 era,’ and the time from 2023 onward—when it secured funding and accelerated clinical trials in response to the changing competitive landscape—as the ‘1.5 era.’
The new ‘2.0 era’ aims for qualitative transformation, going beyond mere quantitative growth. The company seeks to accelerate clinical entry for existing pipeline candidates and, starting five years from now, introduce entirely new technologies to the market. CEO Park outlined specific goals: “Within the next five years, we will secure 20 best-in-class and first-in-class ADC new drug pipeline candidates and expand our investments into new modality sectors.” To support this, the company has proactively secured a total of 1 trillion won in funding, including 500 billion won raised through the National Growth Fund. CEO Park added, “With 1 trillion won in funds, Rigakem Bioscience intends to pioneer a path never before taken by Korean bio companies.”
Detailed research and commercialization strategies were also discussed. Chief Technology Officer (CTO) Jinhwan Han introduced next-generation platform strategies to overcome the chronic challenges of ADCs—namely, drug resistance and toxicity—and to expand indications. The company aims to identify a new ‘topoisomerase I inhibitor’ to replace the widely used camptothecin (CPT) class, thereby fundamentally addressing resistance issues. In addition, they are accelerating research to combine novel mechanisms of action (MoA), such as targeted protein degraders (TPD) and immune stimulators, and to develop STING agonists that activate innate immunity exclusively in the tumor microenvironment, thus minimizing systemic toxicity to healthy cells.
Enhancing Corporate Value through Open Innovation and Advanced Late-Stage Clinical Development
The process for discovery and validation of new drug candidates is also being streamlined. From the earliest planning stages, the translational research team is involved in biomarker design, and artificial intelligence (AI)-driven preclinical data analysis models are being introduced to focus research resources on selecting candidates with the highest probability of success. Research Center Director Cheolwoong Jung reiterated the need for external collaboration, stating, “We cannot do everything ourselves, nor do we need to. It is extremely important to find partners with whom we can quickly move ahead by combining their expertise with our own mature technologies. In fact, we are engaged in in-depth joint research discussions from multiple angles on an almost daily basis.”
The company’s two-track strategy to strengthen business capabilities is also gaining momentum. Previously, due to the heavy cost burden of new drug development, Rigakem Bioscience mainly transferred technology to partners at the non-clinical or early clinical stages. Now, with sufficient liquidity secured, the company will internalize the design of antibodies and directly oversee the clinical development of promising, high-value assets through to late-stage trials, thereby increasing value creation.
Chief Business Development Officer (CBDO) Jaewook Chae noted, “In the past, non-clinical stage deals typically totaled 700 to 800 million dollars (approximately 1.0586 to 1.2098 trillion won), with upfront payments in the range of 30 to 50 million dollars (about 45.3 to 75.6 billion won). For the technology transfer deal with Johnson & Johnson, we received an upfront payment of 100 million dollars (about 151.2 billion won) even without patient data.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Regarding the company’s future direction, he added, “We are no longer in a position to sign contracts quickly and lower our value as before. In addition to simple financial gains, we are preparing a ‘package big deal’ that will benefit the company in a variety of ways.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.